Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms
Jürgen Thiele, Hans Michael Kvasnicka, Attilio Orazi, et al.
American Journal of Hematology (2022) Vol. 98, Iss. 1, pp. 166-179
Closed Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 190
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 5, pp. 801-821
Open Access | Times Cited: 160
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1465-1487
Open Access | Times Cited: 72
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
Ayalew Tefferi, Alessandro M. Vannucchi, Tiziano Barbui
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 697-718
Open Access | Times Cited: 37
Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review
Samuel Bogdan Todor, Cristian Ichim, Adrian Boicean, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 8, pp. 8407-8423
Open Access | Times Cited: 17
Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib
Francesco Passamonti, Siddhi Korgaonkar, Rohan Parikh, et al.
Future Oncology (2025), pp. 1-13
Open Access | Times Cited: 1
Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification
Jürgen Thiele, H. M. Kvasnicka, Umberto Gianelli, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
Haematologica (2023) Vol. 108, Iss. 11, pp. 2919-2932
Open Access | Times Cited: 36
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Ayalew Tefferi, Hassan B. Alkhateeb, Naseema Gangat
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices
Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
American Journal of Hematology (2024) Vol. 99, Iss. 2, pp. 300-308
Closed Access | Times Cited: 9
A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count
Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 12, pp. 1829-1837
Open Access | Times Cited: 19
The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms
Jürgen Thiele, Hans Michael Kvasnicka, Attilio Orazi, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 544-545
Open Access | Times Cited: 13
Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
Marko Lucijanić, Ivan Krečak, Ena Sorić, et al.
Life (2024) Vol. 14, Iss. 4, pp. 523-523
Open Access | Times Cited: 4
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Annals of Hematology (2025)
Open Access
Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system
E. Walter, Francesca Torelli, Tiziano Barbui
Annals of Hematology (2025)
Open Access
Hemoglobin levels for the diagnosis of polycythemia Vera: How high is high enough?
Uğur Koca, Enes Seyda Şahiner, Özge Soyer Kösemehmetoğlu, et al.
European Journal of Internal Medicine (2025)
Closed Access
Development and Validation of a User‐Friendly Predictive Model Using Demographic and Complete Blood Count Data to Facilitate Early Diagnosis on Suspicion of Myeloproliferative Neoplasms
Lilan Jin, Lei Li, Yiyi Lu, et al.
International Journal of Laboratory Hematology (2025)
Closed Access
Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management
Tiziano Barbui, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology (2025)
Closed Access
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation
Hiroyuki Takamori, Ying‐Jung Huang, Hidehito Fukushima, et al.
Leukemia (2025)
Closed Access
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies
Jean‐Jacques Kiladjian, Bruno Cassinat
American Journal of Hematology (2023) Vol. 98, Iss. 5, pp. 794-800
Open Access | Times Cited: 9
Current and emerging sequencing-based tools for precision cancer medicine
Anders Edsjö, David Gisselsson, Johan Staaf, et al.
Molecular Aspects of Medicine (2024) Vol. 96, pp. 101250-101250
Closed Access | Times Cited: 3
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
Alessandro Laganà, Mauro Passucci, Sara Pepe, et al.
European Journal Of Haematology (2024) Vol. 112, Iss. 6, pp. 938-943
Closed Access | Times Cited: 3
Erythrocytosis: Diagnosis and investigation
Iman Al Noumani, Claire Harrison, Mary Frances McMullin
International Journal of Laboratory Hematology (2024) Vol. 46, Iss. S1, pp. 55-62
Open Access | Times Cited: 3
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
Alessandra Carobbio, Alessandro M. Vannucchi, Elisa Rumi, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients
Tiziano Barbui, Alessandra Carobbio, Jüergen Thiele, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top